BFK Stock Overview
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Pharmesis International Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.08 |
| 52 Week High | S$0.14 |
| 52 Week Low | S$0.08 |
| Beta | 0.26 |
| 1 Month Change | -38.93% |
| 3 Month Change | n/a |
| 1 Year Change | -27.27% |
| 3 Year Change | -62.79% |
| 5 Year Change | -80.00% |
| Change since IPO | -97.95% |
Recent News & Updates
Shareholder Returns
| BFK | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -2.8% |
| 1Y | -27.3% | -2.6% | -8.3% |
Return vs Industry: BFK underperformed the SG Pharmaceuticals industry which returned -2.6% over the past year.
Return vs Market: BFK underperformed the SG Market which returned -8.3% over the past year.
Price Volatility
| BFK volatility | |
|---|---|
| BFK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in SG Market | 15.0% |
| 10% least volatile stocks in SG Market | 2.2% |
Stable Share Price: BFK's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BFK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Xuedan Wu | www.pharmesis.com |
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment.
Pharmesis International Ltd. Fundamentals Summary
| BFK fundamental statistics | |
|---|---|
| Market cap | S$2.21m |
| Earnings (TTM) | -S$934.11k |
| Revenue (TTM) | S$8.60m |
0.3x
P/S Ratio-2.4x
P/E RatioIs BFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BFK income statement (TTM) | |
|---|---|
| Revenue | CN¥45.64m |
| Cost of Revenue | CN¥24.82m |
| Gross Profit | CN¥20.82m |
| Other Expenses | CN¥25.77m |
| Earnings | -CN¥4.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 45.61% |
| Net Profit Margin | -10.86% |
| Debt/Equity Ratio | 27.7% |
How did BFK perform over the long term?
See historical performance and comparison